Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tasadenoturev - DNAtrix/University of Texas M. D. Anderson Cancer Center

Next Previous
Drug Profile

Tasadenoturev - DNAtrix/University of Texas M. D. Anderson Cancer Center

Alternative Names: Ad-delta24-RGD; Ad-DNX 2401; Ad5-Delta 24RGD; Ad5-delta24-RGD; Adenovirus DNX 2401; Adenovirus-5 delta 24 RGD; Delta 24 RGD 4C; Delta-24-RGD; Delta-24-RGD-H43m; DNX 2401; IE-CRAd; RGD-delta24; Tasadenoturev

Latest Information Update: 28 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DNAtrix; University of Texas M. D. Anderson Cancer Center
  • Developer Alcyone Therapeutics; Clinica Universidad de Navarra; DNAtrix; Merck & Co; University of Alabama Comprehensive Cancer Center; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma
  • No development reported Diffuse intrinsic pontine glioma; Gliosarcoma; Ovarian cancer; Rhabdoid tumour; Teratoma

Most Recent Events

  • 28 Apr 2025 No recent reports of development identified for phase-I development in Diffuse intrinsic pontine glioma(First-line therapy, In adolescents, In children, In infants) in Spain (Intratumoural, Injection)
  • 28 Apr 2025 No recent reports of development identified for phase-I development in Glioblastoma(Recurrent) in USA (Intra-arterial, Injection)
  • 28 Apr 2025 No recent reports of development identified for preclinical development in Rhabdoid-tumour in USA (Intratumoural, Injection)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top